Aclipse Therapeutics has successfully conducted the US FDA pre-IND meeting for M102. The FDA has reviewed the M102 preclinical data package and confirmed the necessary preclinical studies for M102 to initiate its first-in-human studies. The agency has also provided valuable guidance to support the clinical development of M102.
Aclipse Therapeutics Expands Drug Development Pipeline
Aclipse Therapeutics Expands Drug Development Pipeline with Signing of Exclusive, Worldwide License Agreement with Chong Kun Dang Pharmaceutical Corporation to